Ryusaburo Mori, ·, Shigeru Honda, · Fumi Gomi, ·, Akitaka Tsujikawa, Hideki Koizumi, Haruka Ochi, Shino Ohsawa, · Annabelle Ayame Okada, et al. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Japanese Journal of Ophthalmology. 2023
Mori R, Tanaka K, Yuzawa M. Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity. Medicine. 2018. 97. 25. e11188